Heron Therapeutics shares jumped 17% after the company shared early financial results for the fourth quarter and full year 2025. Investors reacted positively to the numbers. The biggest reason was strong growth from ZYNRELEF.
Heron said its fourth quarter net revenue was around $40.5 million. ZYNRELEF alone brought in about $12.5 million during the quarter. This product showed the fastest growth across the company’s lineup. Sales rose nearly 35% compared to the third quarter of 2025.
For the full year, Heron reported net revenue of roughly $154.9 million. The company sells several hospital focused medicines. APONVIE contributed around $3.8 million in the fourth quarter. CINVANTI generated about $22.9 million. SUSTOL added around $1.3 million.
Management sounded confident about the progress. CEO Craig Collard said the company was encouraged by the strong finish to the year. He highlighted the growing momentum in the acute care business. ZYNRELEF and APONVIE were key drivers. He also said the company made solid progress across many areas during the year.
ZYNRELEF is a non opioid treatment used to manage pain after surgery. Its rising adoption appears to be boosting confidence in Heron’s future. Investors seem to believe the company is gaining traction in the pain management space. The strong fourth quarter performance has strengthened expectations for continued growth ahead.